Skip to content

Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders Study

Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders Study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05108974
Acronym
CHOLINE4
Enrollment
62
Registered
2021-11-05
Start date
2021-10-22
Completion date
2026-07-31
Last updated
2025-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fetal Alcohol Spectrum Disorders

Brief summary

This is a randomized, double-blind controlled trial of choline supplementation in children with Fetal Alcohol Spectrum Disorders (FASD). The study is comparing two administration durations (3 months vs. 6 months) of choline. The primary outcome measures are cognitive measures.

Detailed description

This project is the fourth in a series of randomized, double-blind controlled trials of choline bitartrate in children ages 2-5 (under 6) years with prenatal alcohol exposure. Pre-clinical data suggests that choline may attenuate the cognitive deficits caused by prenatal alcohol exposure (especially memory deficits). This study will evaluate the effects of daily choline supplementation in two dosing regimens (3 months choline vs. 6 months choline). Outcome measures include an elicited imitation memory paradigm, IQ measures, and measures of memory and executive functioning, and behavior.

Interventions

Powdered drink mix for daily consumption

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
Jeff Wozniak
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Months to 72 Months
Healthy volunteers
No

Inclusion criteria

* Ages 2.5 years to 5 years old (\<6 years of age) at enrollment * Prenatal alcohol exposure * Available parent or legal guardian capable of giving informed consent for participation.

Exclusion criteria

* History of a neurological condition (ex. epilepsy, traumatic brain injury) * History of a medical condition known to affect brain function * Other neurodevelopmental disorder (ex. autism, Down syndrome) * History of very low birthweight (\<1500 grams)

Design outcomes

Primary

MeasureTime frameDescription
Elicited Imitation Memory Task (EI) (P.J. Bauer et al 1992 laboratory paradigm)Change from baseline to 9 monthsElicited Imitation short-delay memory measure (percent correct for recall)
Stanford-Binet Intelligence Test (SB-5)Change from baseline to 9 monthsStanford Binet Intelligence Test - 5th Edition
Minnesota Executive Function Scale (MEFS)Change from baseline to 9 monthsMinnesota Executive Function Scale - Early Childhood Version
NIH Toolbox Flanker TestChange from baseline to 9 monthsNIH Toolbox Flanker Inhibitory and Control Test
NIH Toolbox Picture Sequence Memory TestChange from baseline to 9 monthsNIH Toolbox Picture Sequence Memory Test

Secondary

MeasureTime frameDescription
Child Behavior Checklist (CBCL)Change from baseline to 9 monthsChild Behavior Checklist - Parent Report Version

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026